Scope of the Study
The global Gabapentin market is expected to witness high demand due to increasing healthcare expenditure in the forecasted period. Gabapentin is an anti-epileptic drug, also called an anticonvulsant. It affects chemicals and nerves in the body that are involved in the cause of seizures and some types of pain. Dosage is based on medical condition and response to treatment. For children, the dosage is also based on weight. Gabapentin's primary use is to prevent or control seizures. It works by calming down nerve activity to reduce seizure intensity or occurrence. Children and adults can take the drug. Gabapentin is also used in adults to manage a condition called postherpetic neuralgia, which is pain that occurs after shingles. It is not used for routine pain caused by minor injuries or arthritis. Gabapentin is an anticonvulsant.
The market study is being classified and major geographies with country level break-up.
Pfizer (United States), GSK (United Kingdom), Jiangsu Enhua (China), Jiangsu Hengrui (China), Novartis (Switzerland), Actavis (United States) and Glenmark (India) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to avail competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Gabapentin market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Gabapentin market by Type, Application and Region.
On the basis of geography, the market of Gabapentin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Number of Adult Populations
- Rising Application in Restless Legs Syndrome
- High Adoption Due to use in Restless Legs Syndrome
- Rising Demand to Treat Nerve Pain
- The Increasing Concern Regarding Side Effects Of the Gabapentin
- The Ongoing Research and Development Activities
- Increasing Healthcare Expenditure
- Stringent Government Regulation Related to Pharmaceuticals
"FDA is warning that serious breathing difficulties may occur in patients using gabapentin (Neurontin, Gralise, Horizant) or pregabalin (Lyrica, Lyrica CR) who have respiratory risk factors. FDA is requiring new warnings about the risk of respiratory depression to be added to the prescribing information of the gabapentinoids. FDA has also required the drug manufacturers to conduct clinical trials to further evaluate their abuse potential, particularly in combination with opioids, because misuse and abuse of these products together are increasing, and co-use may increase the risk of respiratory depression."
Key Target AudienceGabapentin Manufactures, Gabapentin Suppliers, Gabapentin Distributors, Government Regulatory Bodies, Private Research Organizations and Government Research Organizations
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase